Medical science has been facing the daunting challenge of coping with the Coronavirus, and while vaccination drives are on for all adults, the US has only seen the start of a massive process. A case in point is the extent to which adults have been vaccinated in the US is not equal to the extent to which similar protection has been administered to adolescents, mainly children who are within the age bracket of 12 years to 17 years. One player who has dedicated a massive drive to test and submit results to the government is Moderna.
Is Moderna’s Covid Vaccine Truly Ready For The Markets?
As per a publication on Tuesday, Moderna revealed that the Phase 2/3 trial of its vaccines are complete and have proven to be of equal potential in eliciting the same immune response in adolescents as the vaccines today are eliciting in adults. The trial involved the inoculation of 3732 children who are between the ages of 12-17 years in the United States. The astonishing fact in the trial was that none of the children who were vaccinated tested positive for Corona even after 14 days of the vaccination. Only four children tested positive, which corroborates with the testing data as 100% effective.
How was the test conducted?
Any child who has at least two Covid symptoms or one symptom and had tested positive for the disease were considered for vaccination. The vaccination was done and patients were closely observed for even a single dose. 93% effectiveness was seen in the patients wherein the single dose was enough to prevent milder cases of the disease and almost immediately made the patient recover from the single symptom. The results of this study have not been peer-reviewed so far validated enough to be published. However, Moderna has claimed that vaccine has been well tolerated by adolescents and this means that they can be administered in bulk to young adults all over the USA. There were side effects like headache, fatigue, chills and muscle pain noticed after the second dose, but none after the first dose. Pain at the site of injection was also noticed in a few cases.
Moderna has announced that it will be submitting the vaccine results to US Food and Drug Administration in early June, requesting for authorization to use the vaccine in adolescents. As of now, the vaccine created by Moderna is already authorized for use in people above the age of 18 years. The addition of the new adolescent variant would be a great help to immunize the adolescent crowd greatly. Currently, the company plans to ask for authorization of emergency use of the adolescents’ vaccine and once the data is in after a complete study, it will request for complete vaccination of younger adults. This would come in as a support to the current vaccination cover that the US government has for younger adults.
The Story So Far
Pfizer and BioNTech’s vaccine has been authorized for emergency use in children between the ages of 12 and 17. The Pfizer decision had been announced without a meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee, which operates independently. Therefore, the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices sat to quickly review the Pfizer vaccines efficacy in adult and solemnized the decision. Pfizer is now testing vaccines for children between the ages of 6 months to 11 years. It is well understood that a varied number of dosages will be applicable in the case of children between the age of 6 months and 11 years, and this is currently being tried and tested with close observation of the candidates undergoing the trial. Children do not test positive soon after vaccination, but other side effects are being observed to prevent any severe onset of organ inflammation or fever in the kids.